Abstract:The microbial community inhabiting the human gut resembles a bustling metropolis, wherein beneficial bacteria play pivotal roles in regulating our bodily functions. These microorganisms adeptly break down resilient dietary fibers to fuel our energy, synthesize essential vitamins crucial for our well-being, and maintain the delicate balance of our immune system. Recent research indicates a potential correlation between alterations in the composition and activities of these gut microbes and the development of coronary artery disease (CAD). Consequently, scientists are delving into the intriguing realm of manipulating these gut inhabitants to potentially mitigate disease risks. Various promising strategies have emerged in this endeavor. Studies have evidenced that probiotics can mitigate inflammation and enhance the endothelial health of our blood vessels. Notably, strains such as Lactobacilli and Bifidobacteria have garnered substantial attention in both laboratory settings and clinical trials. Conversely, prebiotics exhibit anti-inflammatory properties and hold potential in managing conditions like hypertension and hypercholesterolemia. Synbiotics, which synergistically combine probiotics and prebiotics, show promise in regulating glucose metabolism and abnormal lipid profiles. However, uncertainties persist regarding postbiotics, while antibiotics are deemed unsuitable due to their potential adverse effects. On the other hand, TMAO blockers, such as 3,3-dimethyl-1-butanol, demonstrate encouraging outcomes in laboratory experiments owing to their anti-inflammatory and tissue-protective properties. Moreover, fecal transplantation, despite yielding mixed results, warrants further exploration and refinement. In this comprehensive review, we delve into the intricate interplay between the gut microbiota and CAD, shedding light on the multifaceted approaches researchers are employing to leverage this understanding for therapeutic advancements.

GW29-e0171 the Potential Impact of Intestinal Microbiota Community on Cardiac Valve Calcification and Coronary Artery Disease

Gut Microbes in Cardiovascular Diseases and Their Potential Therapeutic Applications

The Gut Microbiota and Its Interactions with Cardiovascular Disease

Intestinal Flora: A Potential New Regulator of Cardiovascular Disease.

Implication of Gut Microbiota in Cardiovascular Diseases

The role of intestinal microbiota in cardiovascular disease

Gut Microbiota, Metabolites, and Cardiovascular Diseases

Unlocking Cardioprotective Potential of Gut Microbiome: Exploring Therapeutic Strategies

Intestinal Flora Derived Metabolites Affect the Occurrence and Development of Cardiovascular Disease

Causal Effects of Gut Microbiome on Cardiovascular diseases: A Two-Sample Mendelian Randomization Study

Gut microbiota and microbiota-derived metabolites in cardiovascular diseases

Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review)

Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation

Endocrine organs of cardiovascular diseases: Gut microbiota

Alterations in the Gut Microbiome and Metabolism with Coronary Artery Disease Severity.

The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases

Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease

The Gut Microbiome in Atherosclerotic Cardiovascular Disease.

Alterations in Gut Microbiota and Host Transcriptome of Patients with Coronary Artery Disease

The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease

Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review)